Drug intelligence / Profile preview

ESN5800

Development stage: Preclinical
Lead developer: Beijing Yisheng Biotechnology
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Islet Cell Transplantation

Overview

ESN5800 is an allogeneic cell therapy consisting of pluripotent stem cell-derived islet cells, developed by Beijing Yisheng Biotechnology (also known as Essentia Biosciences), a subsidiary of LakeShore Biopharma. The therapy utilizes induced pluripotent stem cells (iPSC) or embryonic stem cells (ESC) that are differentiated into functionally mature islet cells or cell clusters. These cells are intended for transplantation into patients with type 1 diabetes to restore endogenous insulin production and pancreatic islet function. ESN5800 is currently in the preclinical research stage, with plans to initiate Phase 1 clinical trials in China and the United Kingdom.

Other names: 干细胞胰岛药物Stem Cell Islet Drug

Beyond the preview

Go deeper on ESN5800.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ESN5800.

Explore the full profile